EE

Serial Number 77783924
606

Registration Progress

Application Filed
Jul 17, 2009
Under Examination
Mar 2, 2010
Approved for Publication
Dec 8, 2009
Published for Opposition
Dec 8, 2009
Registered

Trademark Image

EE

Basic Information

Serial Number
77783924
Filing Date
July 17, 2009
Published for Opposition
December 8, 2009
Abandonment Date
October 3, 2011
Drawing Code
5000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 3, 2011
Classes
005

Rights Holder

Epigenesis Pharmaceuticals, LLC

16
Address
2009 Eastpark Boulevard
Cranbury, NJ 08512

Ownership History

Epigenesis Pharmaceuticals, LLC

Original Applicant
16
Cranbury, NJ

Epigenesis Pharmaceuticals, LLC

Owner at Publication
16
Cranbury, NJ

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

24 events
Date Code Type Description Documents
Oct 21, 2011 UNDN O UNDELIVERABLE MAIL - NO ACTION TAKEN Loading...
Oct 3, 2011 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 3, 2011 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
May 5, 2011 WOAR I TEAS WITHDRAWAL OF ATTORNEY RECEIVED Loading...
May 5, 2011 WOAG I WITHDRAWAL OF ATTORNEY GRANTED Loading...
Mar 12, 2011 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 11, 2011 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Mar 11, 2011 EX2G S SOU EXTENSION 2 GRANTED Loading...
Mar 1, 2011 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 1, 2011 EXT2 S SOU EXTENSION 2 FILED Loading...
Sep 2, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 31, 2010 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 31, 2010 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 31, 2010 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 2, 2010 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 8, 2009 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 8, 2009 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 3, 2009 ALIE A ASSIGNED TO LIE Loading...
Nov 3, 2009 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Oct 19, 2009 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 19, 2009 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 22, 2009 MPMK O NOTICE OF PSEUDO MARK MAILED Loading...
Jul 21, 2009 NWAP I NEW APPLICATION ENTERED Loading...
Jul 21, 2009 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...

Detailed Classifications

Class 005
medical diagnostic and therapeutic preparations for clinical use, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold as a kit, namely, inhalers; medical preparations, namely, nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of The mark consists of stylized letter "E" connected to another transposed stylized letter "E" in a top to bottom alignment.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
EPIGENESIS

Classification

International Classes
005